LF11 TFA, CAS No.832729-13-2(free basis)

CAS: 832729-13-2(free basis) Cat. No.: L287534 Formule: C69H112N26O14(free basis) Poids moléculaire: 1529.81(free basis)
DISPONIBLE À COMMANDE
QUALITÉ & PURETÉ ≥98%
★
Taille
USA
Allemagne (EU)*
Prix
Qté
1mg
L287534-1mg
3 En stock
—
149,90$US
5mg
L287534-5mg
3 En stock
—
199,90$US
10mg
L287534-10mg
3 En stock
—
319,90$US
25mg
L287534-25mg
3 En stock
—
639,90$US
50mg
L287534-50mg
1 En stock
—
1 039,90$US
Enter a quantity for the sizes you want to add.

Vue d’ensemble

LF 11 TFA exhibits antibacterial activities and can be used for the development of endotoxin-neutralizing and antibacterial agents.

Spécifications

Product Name
LF11 TFA, CAS No.832729-13-2(free basis)
Spécifications et pureté
≥98%
Mécanismes biochimiques et physiologiques
Peptide based on the lipopolysaccharide (LPS)-binding region of human lactoferricin. Neutralizes LPS; displays antimicrobial activity against Gram-negative and Gram-positive bacteria. Analoglauryl-LF 11 available.
Séquence
FQWQRNIRKVR(Modifications: Arg-11 = C-terminal amide)
Type d'action
INHIBITOR
CAS
832729-13-2(free basis)
Type de molécule
Peptide
Stockage et expédition
Conditions de stockage de stockage
Store at -20°C
Expédié en
Ice chest + Ice pads

Données avancées

Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

10 results found

Lot NumberCertificate TypeDateArticle
A2417401A2417401Certificate of AnalysisNov 17, 2026 L287534
A2417402A2417402Certificate of AnalysisNov 17, 2026 L287534
A2417403A2417403Certificate of AnalysisNov 17, 2026 L287534
A2417404A2417404Certificate of AnalysisNov 17, 2026 L287534
A2417405A2417405Certificate of AnalysisNov 17, 2026 L287534
A2417406A2417406Certificate of AnalysisNov 17, 2026 L287534
A2417407A2417407Certificate of AnalysisNov 17, 2026 L287534
A2417411A2417411Certificate of AnalysisNov 17, 2026 L287534
A2417412A2417412Certificate of AnalysisNov 17, 2026 L287534
A2417415A2417415Certificate of AnalysisNov 17, 2026 L287534
Calculateurs de solution
Avis

Avis des clients

Application Protocols

No validated, item-specific protocols (e.g., WB/IHC/IF/FC) are provided in the Product Data for LF11 TFA.

General handling protocol for research use (non-validated, guidance only):

  • Allow vial to warm to room temperature in a desiccator before opening.
  • Reconstitution: start with ultrapure water or buffer; if insoluble, add small DMSO aliquots or 0.1% acetic acid to aid dissolution. Record final solvent composition.
  • Filtration: for sterile applications, 0.22 μm filter into sterile vials.
  • Stock solutions: prepare concentrated stocks (e.g., 1–10 mM if solubility permits) and aliquot to avoid freeze–thaw.
  • Assay addition: dilute stocks into assay media to the desired final concentration, keeping co-solvents at minimal levels (≤0.1–1% v/v).

For any specific bioassay or conjugation workflow, optimize conditions empirically and consult the CoA/SDS for compatibility and safety.

Biological Roles

Item-specific biological role

  • Not specified for this item; refer to primary literature and the product’s CoA for any sequence-specific annotations.

General context (no medical/clinical claims)

  • Research peptides and peptide-like molecules are frequently used as chemical probes to study protein–protein interactions, receptor binding, membrane interactions, or enzyme recognition motifs.
  • Salt form (TFA) does not define biological function but can influence assay pH and ionic strength; consider desalting or buffer exchange prior to sensitive biophysical measurements (e.g., ITC, MST, SPR, NMR).
  • When sequence contains aromatic residues (e.g., Trp/Tyr/Phe), intrinsic UV/fluorescence signals may be leveraged for binding or folding studies; confirm for this item via CoA/sequence disclosure.

Any use is strictly for research only as stated in the product data.

Buffer Applications

This product is a peptide or peptide-like TFA salt and is not a buffering agent. Therefore, classic buffer system guidance (e.g., phosphate, Tris, HEPES) is not directly applicable.

Practical handling in buffered systems (general guidance):

  • Dissolve first in water or minimal DMSO, then dilute into the target assay buffer to the desired concentration.
  • If solubility is limited, slightly acidify the solvent (e.g., 0.1% acetic acid) and then adjust pH after dissolution. Avoid overshooting pH changes that could denature sensitive proteins.
  • For electrophysiology or cell-based assays, ensure final osmolarity and pH are maintained; typically keep co-solvents ≤0.1–1% v/v.
Green Alternatives

Environmental considerations (general)

  • Trifluoroacetate (TFA) is persistent and can impact MS sensitivity; peptide salts with TFA may introduce fluorinated waste.

Greener counterion/solvent strategies (general guidance; not item-specific requirements)

  • Counterion exchange: convert TFA salt to acetate or formate via dissolution in minimal water/acetic acid or formic acid, followed by lyophilization. This can improve MS compatibility and reduce fluorinated waste.
  • Mobile phases: replace TFA-containing eluents with formic or acetic acid for LC–MS workflows when sensitivity is needed.
  • Solvent choice hierarchy: prioritize water and aqueous buffers; use MeCN and alcohols judiciously; reserve HFIP/TFE for last resort due to environmental/health concerns.

Trade-offs

  • TFA salts often exhibit better solid-state stability and sometimes improved solubility versus acetate; removing TFA may modestly alter solubility and chromatographic behavior.
  • Formic/acetic acids provide MS-friendly ionization but may slightly reduce chromatographic resolution compared to TFA in RP-HPLC.

Implement green measures compatible with your assay and regulatory framework; validate any counterion exchange to ensure identity and purity are maintained.

Pharmaceutical Uses

No pharmaceutical grade or excipient designation is provided for this product. It is supplied for research use only.

General formulation context (not specific to this item):

  • Peptide TFA salts are sometimes used in early pre-formulation studies to assess solubility and stability; however, TFA counterions are often avoided in final drug products due to regulatory and analytical considerations.
  • For formulation experiments, researchers may perform counterion exchange (e.g., to acetate, citrate, or HCl) to improve compatibility with downstream processes.

This listing makes no claims for clinical or therapeutic use and provides no pharmacopeial compliance data. Consult the CoA if excipient or GMP-related information becomes available, or source an appropriate grade for regulated applications.

Physical Properties

Item-specific (from Product Data)

  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Boiling point, melting point, density, refractive index, logP, pKa, UV cutoff: Not specified for this item; refer to CoA/Spec Sheet.

General expectations for peptide TFA salts (literature/general knowledge; not item specifications)

  • Physical state: typically white to off-white amorphous solid or lyophilized powder.
  • Thermal behavior: may soften/decompose before a sharp melt; drying is often performed under high vacuum at ambient to 40°C.
  • Solubility profile: many peptide TFA salts are soluble in water, aqueous buffers (pH-dependent), and polar aprotic solvents (e.g., DMSO). Some require acidified aqueous media (e.g., 0.1% TFA or acetic acid) to aid dissolution.
  • Hygroscopicity: peptide salts can be hygroscopic; exposure to ambient moisture may alter mass and apparent concentration.
  • Ion pairing: TFA counterions can promote ion pairing that affects solubility and chromatographic behavior (e.g., in RP-HPLC).
  • pH behavior: dissolution may acidify solutions due to TFA; neutralization or buffer exchange may be required for pH-sensitive assays.

Always verify item-specific values and solubility with the CoA/SDS prior to use.

Quality and Grades

Item-specific (from Product Data)

  • Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

How this product type is commonly characterized (general guidance)

  • Peptide-grade materials are typically released with:
    • Purity by RP-HPLC (area %; note that TFA salt form can influence retention/peak shape).
    • Identity by HRMS/ESI-MS and sometimes Amino Acid Analysis or NMR (where applicable).
    • Counterion content (moles of TFA per mole of base) and residual solvents/water by Karl Fischer/GC, when relevant.
  • If “TFA” form is supplied, expect presence of trifluoroacetate counterions; this may be reported as % TFA or equivalents in the CoA.

Implications of the TFA salt form (general)

  • TFA can enhance solid-state stability and solubility in polar media, but may introduce acid load and can suppress MS ionization in bioanalytical workflows.
  • For biological assays or conjugation protocols sensitive to TFA, consider counterion exchange (e.g., to acetate or HCl) via lyophilization from volatile acids.

For exact acceptance criteria and analytical results, consult the item’s CoA/Spec Sheet.

Reaction and Applications

Scope for a peptide TFA salt in research (general guidance; expand-on-use case)

  • Screening libraries: supplied as part of small-molecule/peptide libraries for biochemical or biophysical screening (binding, enzymatic modulation, or membrane interaction studies). No efficacy claims are implied.
  • Analytical characterization: RP-HPLC for purity profiling; LC–MS/HRMS for identity. Consider counterion exchange for MS-friendly analysis.
  • Bioconjugation: peptides can be modified at N-termini, lysine ε-amines, cysteines (thiols), or carboxylates using NHS-esters, isothiocyanates, maleimides, or carbodiimide chemistry (EDC/NHS).
  • Material sciences: exploration as surface-immobilized ligands on gold, silica, or polymers via thiol–gold, click chemistry, or amide coupling.

Practical tips (general)

  • If counterion load is high, perform desalting or buffer exchange (spin columns, SPE, dialysis) prior to sensitive assays.
  • Verify concentration using UV at 214–220 nm or 280 nm (if aromatic residues present), or amino acid analysis; account for TFA mass in molarity calculations.
  • For structure–activity studies, consider salt form control and pH matching across samples to avoid confounding effects from acid/base state.

Note: Reaction chemistry and applications depend on the actual sequence/functional groups of LF11, which are not specified here. Confirm reactivity with the item’s CoA/SDS before executing transformations.

Reaction Conditions

General conditions for common peptide modifications (literature guidance; adjust to sequence-specific behavior)

  • Amide coupling (N-terminus or side-chain):
    • Solvent: DMF, NMP, or aqueous buffer with water-miscible co-solvent.
    • Reagents: HATU or HBTU with DIPEA (base) at 0–25°C; reaction times 0.5–4 h.
  • NHS-ester acylation (amines):
    • Buffer: pH 7.5–8.5 (e.g., bicarbonate), 4–25°C, 10–120 min; avoid excess base to prevent hydrolysis.
  • Maleimide–thiol conjugation (cysteine):
    • Buffer: pH 6.5–7.5 (phosphate), 0–25°C, 10–60 min; exclude oxidants; include EDTA to limit metal-catalyzed thiol oxidation.
  • CuAAC (azide–alkyne):
    • Solvent: water/t-BuOH/DMSO mixtures; CuSO4 + sodium ascorbate or Cu(I) sources; RT–40°C; minutes to hours; add TBTA ligand to preserve activity.

Workup and purification (general)

  • Quench by dilution and pH adjustment; remove small-molecule reagents via SPE, dialysis, or RP-HPLC.
  • Desalt to remove TFA or coupling byproducts prior to bioassay or MS.

These conditions are illustrative and should be optimized for the actual sequence and functional groups of LF11 (not provided here).

Safety and Handling

Item-specific hazard information

  • Signal word, H-statements, GHS classification, pictograms: Not specified for this item; refer to SDS.

General laboratory precautions (literature/general guidance)

  • Handle peptide TFA salts in a chemical fume hood to minimize inhalation of dust or aerosols.
  • Recommended PPE: lab coat, safety glasses, and suitable gloves (e.g., nitrile). Avoid skin/eye contact and inhalation of particulates.
  • Avoid contact with strong bases (which can deprotonate and release TFA) and strong oxidizers.
  • TFA salts can acidify aqueous solutions; adjust pH cautiously and avoid vigorous neutralizations that generate heat and CO2 if bicarbonates are used.
  • For spills: gently sweep/collect solids with minimal dust generation; rinse area with water/detergent. Dispose according to institutional and local regulations.

First-aid overview (consult SDS for authoritative guidance)

  • Inhalation: move to fresh air; seek medical attention if symptoms persist.
  • Skin/eye contact: rinse with water for at least 15 minutes; remove contaminated clothing; seek medical attention if irritation develops.
  • Ingestion: rinse mouth; do not induce vomiting; seek medical attention.

Store tightly closed, dry, and protected from light at the specified −20°C. Allow cold shipments to equilibrate in a desiccator before opening to prevent condensation.

Solvent Selection

General solvent behavior for peptide TFA salts (literature/general guidance; not item-specific specs)

  • Polarity class: highly polar/ionic; dissolution favors water, aqueous buffers, and polar aprotic solvents (e.g., DMSO, DMF).
  • Miscibility profile:
    • Water: often good to excellent, potentially improved by slight acidification (e.g., 0.1% acetic acid or TFA).
    • Alcohols (MeOH/EtOH): variable; better for small peptides; may require co-solvent.
    • Acetonitrile: typically used as co-solvent with water for HPLC; pure MeCN may be too poor unless aided by acid.
    • Nonpolar solvents (EtOAc, hexanes, toluene): generally unsuitable.

Practical selection tips

  • Start with water or buffer at target pH; if undissolved, add small % DMSO or a few drops of dilute acid (acetic or TFA) to assist.
  • For pH-sensitive systems, dissolve first in minimal DMSO, then dilute into buffer to limit final DMSO to ≤0.1–1% v/v where compatible.
  • For analytical HPLC, use water/MeCN with volatile acids (formic or acetic acid) when downstream MS is anticipated; avoid TFA in mobile phase if sensitivity is critical.

Small comparison (general)

  • Water/buffer: biocompatible, best first choice.
  • DMSO: strong solvency; use sparingly to avoid assay interference.
  • HFIP/TFE: powerful for secondary-structure disruption but less green; reserve for difficult cases.
Storage and Reconstitution

Item-specific storage and shipping (from Product Data)

  • Storage condition: Store at −20°C.
  • Shipping: Ice chest + ice pads.

General best practices for peptide TFA salts (literature/general guidance)

  • Protect from moisture and light. Store in original, tightly capped container; use a desiccant.
  • For long-term storage, consider −20°C to −80°C in a dry environment. Avoid frost-free freezers that cycle temperatures.
  • Upon receipt, allow vial to equilibrate to room temperature in a desiccator before opening to prevent condensation.

Reconstitution guidance (not item-specific specs)

  • Solvents: Water or buffer are first choices; if needed, use DMSO or minimal dilute acid (e.g., 0.1% acetic acid) to aid dissolution.
  • Concentration verification: determine by UV absorbance (214–220 nm; or 280 nm if aromatic residues present) or by weighing under dry conditions; account for TFA mass when calculating molarity.
  • Aliquoting: prepare single-use aliquots and store at −20°C or below. Avoid repeated freeze–thaw cycles.
  • Stability in solution: peptide solutions are generally most stable at low temperature and neutral to slightly acidic pH; for multi-day use, consider 0.02% sodium azide if compatible and not intended for live-cell systems.

Always defer to the product’s CoA and SDS for definitive storage limits, stability windows, and any item-specific instructions.

Structure and Identity

Item-specific (from Product Data)

  • Product name: LF11 TFA (trifluoroacetate salt)
  • SKU: L287534
  • CAS: 832729-13-2 (free basis)
  • Storage: Store at −20°C
  • Shipped: Ice chest + ice pads
  • Category: Small molecules & compound libraries (research use only)

Not specified for this item; refer to CoA/Spec Sheet

  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES / InChI / InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
  • Grade/Purity, Appearance: Not specified for this item; refer to CoA/Spec Sheet.

General structural context (literature/general knowledge, not item-specific)

  • The designation “TFA” indicates a trifluoroacetate counterion, commonly used to isolate peptides or basic amine–containing molecules as stable salts.
  • “LF11” nomenclature is consistent with a peptidic sequence or peptide-like small molecule; the exact sequence/structure for this item is not provided here.
  • Typical 2D description for peptide TFA salts: a backbone of amide linkages (–CONH–) with side chains bearing various functional groups; cationic centers (e.g., protonated amines) are balanced by TFA− anions.
  • Counterion content (number of TFA equivalents per molecule) depends on the total basic sites in the free base and workup conditions (to be confirmed by CoA).
Synthetic Utility

General synthetic considerations for peptide TFA salts (not item-specific)

  • Functional handles typical of peptides include: α-amines/N-termini, ε-amines (Lys), thiols (Cys), carboxylates (Asp/Glu/C-terminus), and occasionally azides/alkynes if pre-installed.
  • Common transformations:
    • Amide coupling (EDC/HOBt, HATU, PyBOP) to extend or derivatize termini.
    • NHS-ester acylation or isothiocyanate labeling on primary amines.
    • Maleimide–thiol conjugation at cysteine residues for fluorescent tags or cargo attachment.
    • Click chemistry (CuAAC, SPAAC) when azide/alkyne handles are present.
  • Purification: RP-HPLC with volatile modifiers (formic/acetic acid) preferred if MS detection is planned; TFA in eluents can suppress MS signals.
  • Salt management: prior to synthesis or conjugation, consider neutralization or counterion exchange to minimize TFA interference and to improve reaction kinetics.

Because the exact sequence/functional groups of LF11 are not provided, verify reactive sites experimentally (e.g., by TNBS assay for amines, Ellman’s for thiols) before designing coupling strategies.

Target Specificity

No target, epitope, or specificity information is provided for this product. There are no antibodies or biologic targeting claims associated in the Product Data.

Item-specific details such as receptor, enzyme, or membrane targets are not specified for this item; refer to CoA/Spec Sheet or primary literature if disclosed elsewhere.

Foire aux questions

What is the purity of this product?
This product is supplied at ≥98% purity (chemical assay). Lot-specific values are stated on the Certificate of Analysis.
How should this product be stored?
Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.
How is this product shipped?
This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 832729-13-2(free basis).
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Souhaitez-vous que nous vous envoyions un message lorsque des réductions seront disponibles?

Me rappeler plus tard

Merci ! Veuillez vérifier votre boîte de réception e-mail pour confirmer.

Oups ! Les notifications sont désactivées.